Abstract
Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.
Keywords: Immunotherapy, programmed death-1, prognosis, prostate cancer, vaccines.
Current Drug Targets
Title:Emerging Immunotargets and Immunotherapies in Prostate Cancer
Volume: 17 Issue: 7
Author(s): Rodolfo Montironi, Matteo Santoni, Valeria Sotte, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Rossana Berardi and Marina Scarpelli
Affiliation:
Keywords: Immunotherapy, programmed death-1, prognosis, prostate cancer, vaccines.
Abstract: Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo- or radiation therapy.
Export Options
About this article
Cite this article as:
Montironi Rodolfo, Santoni Matteo, Sotte Valeria, Cheng Liang, Lopez-Beltran Antonio, Massari Francesco, R. Matrana Marc, Moch Holger, Berardi Rossana and Scarpelli Marina, Emerging Immunotargets and Immunotherapies in Prostate Cancer, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450117666160217123304
DOI https://dx.doi.org/10.2174/1389450117666160217123304 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Stress, Aging and Reliability of Antioxidant Enzyme Defense
Current Aging Science MicroRNA-7 Regulates Insulin Signaling Pathway by Targeting IRS1, IRS2, and RAF1 Genes in Gestational Diabetes Mellitus
MicroRNA HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism Use of Corticosteroids in Critically Ill Septic Patients: A Review of Mechanisms of Adrenal Insufficiency in Sepsis and Treatment
Current Drug Targets Mechanisms of Developing Post-Traumatic Stress Disorder: New Targets for Drug Development and Other Potential Interventions
CNS & Neurological Disorders - Drug Targets Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Antigonadotropins: A Novel Strategy to Halt Alzheimers Disease Progression
Current Pharmaceutical Design Novel Chiral LC Methods for the Enantiomeric Separation of Bicalutamide and Thalidomide on Amylose Based Immobilized CSP
Current Pharmaceutical Analysis Recent Developments of Steroid Sulfatase Inhibitors as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Dual Carbonic Anhydrase - Cyclooxygenase-2 Inhibitors
Current Topics in Medicinal Chemistry Toxicity Burden in Head and Neck Cancer: Past, Present, and Future Strategies
Current Cancer Therapy Reviews Role of microRNAs in Chronic Lymphocytic Leukemia Pathogenesis
Current Medicinal Chemistry Pharmaceutical Nanotechnology United States Patent Watch (July to September 2016)
Pharmaceutical Nanotechnology The Cone Beam O-Arm Imaging System: Radiation Dose, Image Quality, and Clinical Applications
Recent Patents on Medical Imaging Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Virtual Screening of Natural Products Database
Mini-Reviews in Medicinal Chemistry MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Production and Application of Copper Radiopharmaceuticals
Current Radiopharmaceuticals